RabPharma

RabPharma is a UK-based biotechnology company specializing in the development of small molecule inhibitors targeting Rab GTPases, specifically Rab27a and Rab27b. Spun out from the University of Manchester, the company focuses on disrupting the secretion of pro-tumorigenic exosomes and extracellular vesicles that drive cancer metastasis and chemoresistance. By inhibiting these specific intracellular trafficking pathways, RabPharma aims to provide novel therapeutic options for hard-to-treat cancers such as breast cancer and melanoma. The company's platform leverages deep expertise in Rab protein biology to identify and optimize potent, selective inhibitors for clinical development. RabPharma is currently advancing its lead candidates through pre-clinical validation to address significant unmet needs in oncology.